Capital International’s Ascendis Pharma ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.76M Sell
12,098
-4,296
-26% -$1.09M 0.09% 135
2026
Q2
$4.37M Hold
16,394
– – 0.14% 115
2026
Q1
$3.75M Sell
16,394
-467
-3% -$105K 0.14% 117
2025
Q4
$3.6M Sell
16,861
-4,811
-22% -$994K 0.13% 123
2025
Q3
$4.31M Buy
21,672
+1,174
+6% +$219K 0.16% 118
2025
Q2
$3.54M Buy
20,498
+297
+1% +$48.4K 0.14% 119
2025
Q1
$3.15M Buy
20,201
+1,048
+5% +$150K 0.14% 119
2024
Q4
$2.64M Buy
+19,153
New +$2.52M 0.11% 129

Other funds holding ASND

Capital International's ASND Position: Q3 2026 in Review

Capital International reduced its Ascendis Pharma (ASND) stake by 26% in Q3 2026, selling an estimated $1.09M and leaving 12,098 shares worth $2.76M. The position accounts for 0.09% of the portfolio, ranked #135.

Capital International first reported a position in ASND in Q4 2024 and has held it in 8 quarters since. The position peaked at $4.37M in Q2 2026. 347 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

  • Capital International held 12,098 shares of Ascendis Pharma worth $2.76M as of Q3 2026.
  • Capital International sold 4,296 Ascendis Pharma shares in Q3 2026, an estimated $1.09M.
  • Ascendis Pharma made up 0.09% of Capital International's portfolio in Q3 2026, its #135 holding.
  • Capital International first reported a position in Ascendis Pharma in Q4 2024 and has held it in 8 quarters since.
  • Capital International's Ascendis Pharma position peaked at $4.37M in Q2 2026.
  • 347 funds tracked by Wall St. Rank held Ascendis Pharma as of Q3 2026.

Based on Capital International's 13F filing for Q3 2026, filed 12 Nov 2026.